Program
tapinarof
Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.
Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.
Drug pageTapinarof: every studyMany companies study it; this page follows only the 25 they lead. All 34 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 121 open or running | phase 4since Dec 26, 2022 | May 16, 2019 | Aug 2027phase 3 · NCT07265479 |
| GlaxoSmithKline | 80 open or running | phase 3since Jun 27, 2017 | Oct 31, 2013 | none ahead |
| Welichem Biotechits history only | 30 open or running | phase 2since Feb 3, 2009 | Feb 3, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | none ahead |
Also a collaborator on its studies: Teva Pharmaceuticals, IQVIA Biotech, PPD DEVELOPMENT, LP, Q2 Solutions and iCardiac Technologies.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 31, 2013First study: phase 1 study in PsoriasisFirst studyNCT01984775 · 52 enrolled · United States, Germany
- Mar 6, 2015Phase 1 study in Dermatitis, AtopicNCT02411162 · 15 enrolled · United States
- May 21, 2015Phase 1 study in Dermatitis, AtopicNCT02466152 · 11 enrolled · Canada
- Sep 17, 2015Phase 1 study in Dermatitis, AtopicNCT02637206 · 26 enrolled · Japan
- Sep 28, 20152 phase 2 studiesNCT02564055, NCT02564042
- Dec 9, 2016Named tapinarofINNProposed as its International Nonproprietary Name in WHO's List 116 · before, WBI-1001
- Jun 27, 2017Phase 3 study in PsoriasisNCT03202004
- Jun 27, 2017Phase 1 study in PsoriasisNCT03201978
TargetBeta
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule
Studies
All 8 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03202004Psoriasis | 3 | Withdrawn | Sep 28, 2018 | 0 |
| NCT03201978Psoriasis | 1 | Withdrawn | May 15, 2018 | 0 |
| NCT02564055Dermatitis, Atopic · United States, Canada, Japan | 2 | Completed | Jan 1, 2017 | 247 |
| NCT02564042Psoriasis · United States, Canada, Japan | 2 | Completed | Oct 1, 2016 | 227 |
| NCT02637206Dermatitis, Atopic · Japan | 1 | Completed | Dec 2, 2015 | 26 |
| NCT02466152Dermatitis, Atopic · Canada | 1 | Completed | Oct 27, 2015 | 11 |
| NCT02411162Dermatitis, Atopic · United States | 1 | Completed | Sep 24, 2015 | 15 |
| NCT01984775Psoriasis · United States, Germany | 1 | Completed | Jul 2, 2014 | 52 |
How it is read
Names in the registry
- “Tapinarof cream, 1%”, 4 entries
- “tapinarof cream, 1%”, 4 entries
- “WBI-1001”, 3 entries
- “Tapinarof”, 2 entries
- “GSK2894512 1% Cream”, 2 entries
Codes read as this program: GSK2894512.
Conditions, from the studies’ own filings
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Skin Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.